<DOC>
	<DOCNO>NCT01461876</DOCNO>
	<brief_summary>This retrospective longitudinal study evaluate prevalence incidence overweight/obesity within HIV-infected population 12 24 month stable antiretroviral therapy ( ART ) . The study group compare weight healthy , matched population infect HIV . The primary hypothesis state proportion HIV-infected person newly classify overweight/obese increase â‰¥20 % 12 month initial ART , incidence great match HIV-uninfected control population . The effect immune function variable , CD4 , HIV viral load , ART regimen weight analyze . In addition , study analyze effect weight immune function marker inflammatory marker , high sensitivity C-reactive protein ( hsCRP ) D-dimer . An HIV sample repository use specimen assay hsCRP D-dimer .</brief_summary>
	<brief_title>Obesity HIV After Antiretroviral Therapy</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<criteria>Inclusion Criteria HIVinfected cohort : 1 . Treatmentnaive study entry ; 2 . Subjects need remain ART 12 month initiate substitution allow toxicity management within class drug ; 3 . Subjects within group remain ART additional 12 month ( total 24 month ) initiate substitution allow toxicity management within class drug continue follow longitudinally 24 month period ; 4 . Availability repository sample . Inclusion Criteria Control Cohort : Followed Duke Primary Care Clinics year inclusion available data weight , race gender . Exclusion Criteria HIVinfected cohort : 1 . Pregnancy period observation within 6 month study entry ; 2 . Malignancy ( squamous basal cell carcinomas skin ) ; 3 . Newly diagnose thyroid disorder within 6 month study entry ; 4 . Use megace marinol ; 5 . Longterm use glucocorticoid ( great 1 month prednisone 5mg high equivalent dose another glucocorticoid ) ; 6 . Use androgenic steroid ; 7 . History diabetes use glucoselowering agent ; 8 . Use follow psychiatric anticonvulsant agent thioridazine , olanzapine ( zyprexa ) , clozapine ( clozaril ) , quetiapine ( seroquel ) , risperidone ( risperdal ) , lithium , remeron , paxil , valproate , carbamazepine , gabapentin ; 9 . Concurrent treatment hepatitis C infection ; 10 . Diagnosis new opportunistic infection ( OI ) define CDC 1st 12 month ART.22 OIs include follow : PCP , toxoplasmosis , MAC , histoplasmosis , candidiasis , cryptococcus , coccidiodes , CMV , cryptosporidium , microsporidiosis , tuberculosis , bartonellosis , herpes simplex virus , HHV8 , human papillomavirus ; 11 . Diagnosis congestive heart failure receive diuretic therapy ; 12 . End stage renal disease . Exclusion Criteria Control Cohort : 1 . Pregnancy period observation within 6 month study entry ; 2 . Malignancy ( squamous basal cell carcinomas skin ) ; 3 . Newly diagnose thyroid disorder within 6 month study entry ; 4 . Longterm use glucocorticoid ( great 1 month prednisone 5mg high equivalent dose another glucocorticoid ) ; 5 . Use androgenic steroid ; 6 . History diabetes use glucoselowering agent ; 7 . Use follow psychiatric anticonvulsant agent thioridazine , olanzapine ( zyprexa ) , clozapine ( clozaril ) , quetiapine ( seroquel ) , risperidone ( risperdal ) , lithium , remeron , paxil , valproate , carbamazepine , gabapentin ; 8 . Treatment hepatitis C infection observation period ; 9 . Diagnosis congestive heart failure receive diuretic therapy ; 10 . End stage renal disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>